Tuesday, October 13, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 25, 2026

What $4,800 a Month Really Looks Like in Retirement at 63

View original at finance.yahoo.com
“Savings: $680,000 in retirement accounts”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Social Security benefits become partially taxable once combined income exceeds $25,000 for single filers, with up to 85% taxable above $34,000

    60% confidence
  • $4,800 a month is close to the median household income in many mid-cost American cities for a single 63-year-old

    60% confidence
  • The break-even point for delaying Social Security from 63 to 67 falls in the late 70s

    60% confidence
  • With a roughly 12% effective federal rate, net monthly income for this retiree lands around $4,224

    60% confidence
  • Claiming Social Security at 63 locks in a permanent 25% reduction (48 months before FRA 67)

    60% confidence
  • Most Americans drastically underestimate how much they need to retire and overestimate how prepared they are

    60% confidence
  • A recent study identified one single habit that doubled Americans' retirement savings

    60% confidence
  • Delaying Social Security to 67 with part-time work to bridge the gap adds hundreds of dollars per month over a 20-year retirement

    60% confidence
  • At $4,800 gross monthly income with $3,070 in fixed costs and taxes, the retiree has zero financial margin for a single car repair or dental emergency

    60% confidence

Data points we hold from this source

Social Security Administration · social security taxability threshold single25000 USD
Social Security Administration · social security 85pct taxable threshold single34000 USD
Social Security Administration · full retirement age67 years
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com